Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Multicenter Study Administering Lapatinib and Capecitabine (Xeloda) in Women With Advanced or Metastatic Breast Cancer

Next Previous
X
Search
Trial Profile

An Open-Label Multicenter Study Administering Lapatinib and Capecitabine (Xeloda) in Women With Advanced or Metastatic Breast Cancer

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Lapatinib (Primary)
  • Indications Advanced breast cancer; Cancer metastases; Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline; GSK; Novartis Pharmaceuticals

    • Most Recent Events

    • 26 Aug 2021 Status changed from completed to discontinued due to primary analysis was completed in 2015 and data collection post 1-Jul-2019 was not reportabledue to local regulations in China. .
    • 13 Jul 2020 Status changed from active, no longer recruiting to completed.
    • 14 Apr 2020 Planned End Date changed from 20 Dec 2021 to 30 Apr 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top